Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
  • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/18—Sulfonamides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4245—Oxadiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
  • A61K31/426—1,3-Thiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/433—Thidiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/10—Drugs for disorders of the urinary system of the bladder
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• This invention describes a new combination of active ingredients for the treatment of bladder dysfunction, in particular mixed incontinence.
• a pharmaceutical active ingredient combination comprising at least one beta-3 adrenoceptor agonist and at least one serotonin and or norepinephrine reuptake inhibitor is presented.
• urinary incontinence is increasing due to the shift in the age structure. However, most of those affected are still not being treated or are being treated inadequately. In addition to the medical complications, such as chronic urinary tract infections, urinary incontinence is associated with a high level of psychological suffering for those affected. An estimated 100 million older people are affected by urinary incontinence.
• the lower urinary tract consists of the urinary bladder, the urethra (urethra), the corresponding muscles and the ligaments of the holding apparatus.
• the function of the bladder is to store and empty the urine.
• For the fulfillment of the memory function is not only the relaxation of the bladder muscle (detrusor muscle), but also closing mechanisms through the bladder neck, the smooth muscles of the urethra and the striated muscles of the urethra and the
• Bladder dysfunction is a heterogeneous group of disorders that differ in terms of their etiology, diagnosis, and therapy.
• urinary incontinence is defined as involuntary urinary loss, which is objectively demonstrable and represents a social and hygienic problem.
• urinary incontinence only occurs if there is an unintended increase in pressure in the bladder during the storage phase. This can be due to unrestrained contractions of the detrusor muscle (urge incontinence) or incompetence of the urethral closing mechanism (stress incontinence).
• OAB overactive bladder
• Contractions during the filling phase are based, the cause of which may be neurogenic or non-neurogenic (idiopathic) in nature.
• Urge incontinence is characterized by irresistible urge to urinate and involuntary loss of urine.
• Stress incontinence is characterized by the involuntary loss of urine, which usually occurs when increased intra-abdominal pressure occurs. This can occur, for example, when lifting, coughing, sneezing, running and when there is no detrusor activity.
• Ham loss occurs as a result of a variable combination of insufficiency of the bladder sphincter muscles and pelvic floor as well as an anatomical defect in the holding apparatus. As a result, the urethral pressure becomes too low and incontinence is the result.
• the WHO recommends treatment with anticholinergics (antimuscarinics).
• anticholinergics antimuscarinics
• their use is limited due to their moderate effectiveness and above all the considerable side effects such as dry mouth, accommodation disorders, constipation, central nervous effects (dizziness, tiredness, nervousness).
• Alpha agonists such as pseudoephedrine and phenylpropanolamine
• Alpha agonists have a very moderate effect in the treatment of mild stress incontinence.
• the disadvantage is that these have no selectivity for the urethral muscles and are associated with frequent side effects such as hypertension, tachycardia, arrhythmia, sleep disorders, headaches and tremors.
• the storage phase of the bladder remains limited and an undisturbed emptying of the bladder without residual urine is guaranteed.
• selective serotonin-norepinephrine reuptake inhibitors are able to stimulate the activity of the pudendal nerve, promote the contraction of the striated sphincter sphincter muscle and thus ensure continence retention.
• Phase III clinical studies have meanwhile shown that the use of a selective serotonin / norepinephrine reuptake inhibitor makes effective drug therapy for stress incontinence possible for the first time.
• the present invention is intended to provide such a contribution to the therapy of urinary incontinence in general, as well as the various forms of training mentioned above.
• a pharmaceutical composition is presented which is intended to combine the advantages of the serotonin and / or norepinephrine reuptake inhibitors as well as those of the beta-3-adrenoceptor agonists in a manner which favors the therapy of the underlying disease.
• a new pharmaceutical composition which comprises (a) at least one serotonin and / or norepinephrine reuptake inhibitor in a pharmaceutically effective amount and (b) a beta-3 adrenoceptor agonist in a pharmaceutically effective amount has active ingredients. a) active components
• Examples of pharmaceutically active salts for each of the compounds that are the subject of this description include, but are not limited to, salts made from pharmaceutically acceptable acids or bases, including organic and inorganic acids and bases. If the compound preferred for use is basic, salts can be prepared from pharmaceutically acceptable acids. When choosing the most preferred salt, or to clarify whether a salt or the neutral compound is used, properties such as bioavailability, manufacturability, processability and storability are taken into account.
• Suitable pharmaceutically acceptable acids include acetic, benzenesulfonic (besylate), benzoic, p-bromophenylsulfonic, camphor sulfonic, carbon, citric, ethanesulfonic, fumaric, gluconic, glutamine, hydrogen bromide, hydrogen chloride, Hydrogen iodide, isethione, milk, maleic, apple, almond, methanesulfone (mesylate), mucin, saltpetre, oxal, pamoa, pantothene, phosphorus, amber, sulfur, wine -, p-toluenesulfonic acid and the like.
• Such pharmaceutically acceptable salts include, but are not limited to, acetate, benzoate, hydroxybutyrate, bisulfate, bisulfite, bromide, butyne-1,4-dioate, caproate, chloride, chlorobenzoate, citrate, dihydrogen phosphate, dinitrobenzoate, fumarate, glycolate , Heptanoate, hexine-1,6-dioate, hydroxybenzoate, iodide, lactate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methoxybenzoate, methylbenzoate, monohydrogenphosphate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, oxalate, phenylproutionate , Phosphate, phthalate, phenyl acetate, propanesulfonate, Propiolate, propionate, pyrophosphate, a
• Tandamine Tandamine, pirandamine, ciclazindole, fluparoxane, lortalamine, talsupram, talopram,
• Prindamine nomifensin, viloxazine, tomoxetine, duloxetine, venlafaxine, milnacipran,
• the selective serotonin and / or norepinephrine reuptake inhibitor is duloxetine, N-methyl-3- (l-naphthalinyloxy) -3- (2-thienyl) propanamine and its pharmaceutically acceptable salts either in its enantiomeric (in particular the (-t -) - enantiomeric) or racemic form and in the most preferred cases the (-t -) - form.
• Duloxetine (+) - N-methyl-3- (1-Na ⁇ hthalinyloxy) -3- (2-thienyl) propanamine is disclosed in U.S. Patent No. US 4,956,388 or US 5,023,269. According to US 5,744,474, the compound can be used to treat urinary incontinence.
• Duloxetine is represented by the following Formula I: Formula (I)
• Duloxetine is preferably used in the form of the hydrochloride salt and as (+) - enantiomer.
• Each of these compounds listed as serotonin / norepinephrine reuptake inhibitors can be used in the indication of urinary incontinence including the subindications stress incontinence, urge incontinence, mixed incontinence or hyperactive bladder listed at the beginning.
• the second component comprises one or more beta-3 adrenoreceptor agonists. This is preferably selected from the following group:
• n 0 or 1
• the enantiomers, diastereomers of the compounds mentioned, optionally tautomers, metabolites or pharmacologically active salts of all the compounds mentioned are also included.
• Beta-3 adrenoceptor agonists of the catecholamine type are preferred. Most preferred are: (-) - ethyl-2- [4- (2- ⁇ [(1 S, 2R) -2-hydroxy-2- (4-hydroxyphenyl) -1-methylethyl] amino ⁇ ethyl) -
• beta-3-adrenoceptor agonists are (-) - ethyl-2- [4- (2- ⁇ [(IS, 2R) -2-hydroxy-2- (4-hydroxyphenyl) -l-methylethyl] amino ⁇ ethyl) -2,5-dimethylphenyloxyacetate or (-) - 2- [4- (2- ⁇ [(IS, 2R) -2-hydroxy-2- (4-hydroxy ⁇ henyl) -l-methylethyl] -amino ⁇ ethyl) -2,5-dimethylphenyloxy] acetic acid, the enantiomers, other diastereoisomers thereof, and pharmacologically active salts thereof.
• Particularly preferred combinations include a combination of (a) duloxetine, either in its enantiomeric or racemic form, or pharmacologically acceptable salts thereof, or any active metabolite thereof, and (b) at least one of the following compounds: (-) - ethyl-2- [4- ( 2 - ⁇ [(IS, 2R) ⁇ 2-hydroxy-2- (4-hydroxyphenyl) -l-methylethyl] amino ⁇ ethyl) -2,5-dimethylphenyloxy] acetate, (-) - ethyl-2- [4- (2- ⁇ [(IS, 2R) -2-hydroxy-2- (4-hydroxyphenyl) -1-methylethyl] amino ⁇ ethyl) -2,5-dimethylphenyloxy] acetate monohydrochloride, (-) - 2- [4 - (2- ⁇ [(1 S, 2R) -2-Hydroxy-2- (4-hydroxyphenyl
• various framework conditions must be taken into account, such as the age and body weight of the patient, the nature and stage of the disease, and the potency of the compound. This is considered to be within the skill of the artisan, and one can consult the existing literature on the components to determine the optimal dosage.
• the indicated dosages refer to the dosage after the end of the adjustment phase.
• the dosages given below expressly include all numerical values, whole or fractional, within the range given.
• the information relates to adult people. Pediatric doses may be lower.
• the preferred dose of the serotonin and / or norepinephrine reuptake inhibitor for humans is between 0.001 mg and 5 g per day, preferably between
• the daily total dose can be taken in one piece or within several servings, depending on the therapy regimen.
• the therapy regiment can also prescribe intervals between receipts that are longer than a day.
• the selection of the dosage of the first component i.e. of serotonin and / or
• Norepinephrine Reuptake Inhibitors is the one that can provide relief to the patient.
• the daily dose when duloxetine is chosen as the active ingredient, the daily dose will be from about 0.1 mg to about 500 mg. More preferably, each dose of the component contains about 0.5 to about 160 mg of the active ingredient.
• This dosage form allows the full daily dose to be administered in half or whole, single or multiple doses. Administrations more than once a day or twice a day (e.g. 3, 4, 5 or 6 administrations per day) are also expressly contemplated herein.
• the average daily adult dose of the other norepinephrine reuptake inhibitors is as follows.
• the dosages explicitly include all numerical values, whole or broken, within the specified range. Pediatric doses may be lower.
• the dosages and regimen (i.e., one, two, three or more administrations per day) of the second component depend on the factors referred to in connection with the dosage choice of the first component.
• the average daily adult dose of the second component (beta-3 agonist) is about 10 mg to about 750 mg per day, preferably 5 to 120 mg, more preferably 10 to 100 mg, administered in one or more doses.
• the metering rods explicitly include all numerical values, whole or fractional, within the range given.
• compositions of the present invention can expediently be administered in a pharmaceutical composition which contains the active components in combination with a suitable carrier.
• a pharmaceutical composition which contains the active components in combination with a suitable carrier.
• Such pharmaceutical compositions can be prepared by methods and contain carriers that are well known in the art. Generally recognized frameworks are available to the specialist in this regard.
• compositions of the present invention can be administered parenterally (e.g. by intravenous, intraperitoneal, subcutaneous or intramuscular injection), topically, orally, administered intranasally, intravaginally, transdermally, rectally, pulmonarily by inhalation or nasally by inhalation, with oral administration being particularly preferred.
• Enteric formulations are preferred among the oral forms of administration. Therefore, gastro-resistant capsules or gastro-resistant tablets are preferred, which can be achieved in both cases, for example, with an enteric coating. Particular care is taken to ensure that the serotonin / norepinehrin reuptake inhibitor is formulated in a gastro-resistant dosage form.
• enteric-coated formulations in the prior art.
• composition according to the invention can be combined with one or more carriers and in the form of ingestible tablets, buccal tablets, sublingual tablets, sugar-coated tablets, powders, powders, pastilles, dragées, granules, capsules, elixirs, suspensions, solutions, syrups , Wafers, chewing gum, food and the like can be used.
• a powder can be produced by grinding the particles of the active substance to a suitable size.
• Diluted powders can be produced by finely grinding the powdery substance with a non-toxic carrier material, such as lactose, and applying it as a powder.
• a non-toxic carrier material such as lactose
• suitable carrier materials are other carbohydrates, such as starch or mannito.
• these powders can contain flavoring agents, preservatives, dispersing agents, colorants and other pharmacological auxiliaries.
• Capsules can be produced from a powder of the type mentioned above or other powders, which are introduced into a capsule, preferably a gelatin capsule, and the capsule is then closed.
• lubricants known from the prior art can be introduced into the capsule or for the closure of the two capsule parts.
• the effectiveness of a capsule when taken orally can be enhanced by adding disintegrating or solubilizing substances, such as, for example, carboxymethyl cellulose, carboxymethyl cellulose calcium, low-substituted hydroxyprophyl cellulose, calcium carbonate, sodium carbonate and other substances.
• the active ingredient can be present in the capsule not only as a solid, but also in suspension, for example in vegetable oil, polyethylene glycol, glycerol with the aid of surface-active substances, etc.
• Tablets can be made by pressing the powdered mixture and then e.g. is processed into granules.
• the tablets can contain various excipients, e.g. Starches, milk sugar, cane sugar, glucose (e.g. for vaginal tablets), sodium chloride, urea for solution u.
• Injection tablets amylose, various types of cellulose as described above and others.
• glycerin or starch can be used as a humectant.
• starch alginic acid, calcium alginate, pectic acid, powdered agar agar, formaldehyde gelatin, calcium carbonate, sodium bicarbonate, magnesium peroxide, amylose can be used as disintegrants.
• cane sugar, stearin, solid paraffin come as counter-disintegrant or solution retarder; Cocoa fat, hydrogenated fats into consideration.
• disintegrants can be: corn starch, potato starch, alginic acid and the like.
• Quaternary ammonium compounds, sodium lauryl sulfate and saponins are suitable as absorption accelerators.
• ether can be used as a binder distributor and cetyl alcohol, glycerol monostearate, starch, corn starch, lactose, wetting agents (e.g. Aerosol OT, Pluronics, Tweens), tragacanth, gum arabic, gelatin and others as a hydrophilizing agent or as a disintegration accelerator.
• wetting agents e.g. Aerosol OT, Pluronics, Tweens
• tragacanth e.g. Aerosol OT, Pluronics, Tweens
• tragacanth e.g. Aerosol OT, Pluronics, Tweens
• gum arabic e.g., tragacanth
• disintegration accelerator e.g., tragacanth
• Sucrose, fructose, lactose or aspartame can be used as sweeteners or peppermint, wintergreen oil, cherry flavor and much more as a flavoring agent
• auxiliaries are generally considered: Aerosil, Aerosol OT ethyl cellulose, amberlite resin, XE-88, Amijel, Amisterol, Amylose, Avicel microcrystalline cellulose, bentonite, calcium sulfate, Carbowax 4000 u.
• auxiliaries can be found in the examples, but other auxiliaries from the prior art can also be used.
• the tablets can be produced, for example, by direct compression.
• connection can be microencapsulated.
• Parenteral administration can be achieved by dissolving the compound in a liquid and injecting it subcutaneously, intramuscularly or intravenously.
• suitable solvents are water or oily media.
• the compound can be mixed with low-melting and water-soluble or water-insoluble materials such as polyethylene glycol, cocoa butter, higher esters (for example moerysthyl, palmitate) or mixtures thereof.
• water-soluble or water-insoluble materials such as polyethylene glycol, cocoa butter, higher esters (for example moerysthyl, palmitate) or mixtures thereof.
• auxiliary substances mentioned are not limited to the use of the application form in the context in which they were mentioned, but can also be transferred to the other application forms.
• any material used in the manufacture of any unit dosage form should be pharmaceutically acceptable and essentially non-toxic in the amounts used.
• the active components can be incorporated into sustained release preparations and devices that include, but are not limited to, those based on osmotic pressures to achieve a desired release profile. Once-daily formulations for each of the active components are specifically included.
• compositions and preparations should contain at least 0.1% active compound.
• the percentage of compositions and preparations can, of course, be varied and may conveniently be between about 0.1 to about 100% by weight of a given unit dosage form.
• the amount of active connection in such therapeutically useful compositions is such that an effective dosage amount is obtained.
• composition of the invention containing the two active components can be administered in the same physical form or simultaneously in accordance with the dosages described above and in the delivery vehicles described above.
• the dosages for each active component can be measured separately and can be administered as a single combined dose or administered separately. They can be administered at the same or different times, as long as both active ingredients are effective in the patient at one time over a 24-hour period. It is preferred if the two components come into effect in such a way that an effect is achieved which is improved compared to the respective individual effect.
• Simultaneous or co-administration means that the patient takes one drug within about 5 minutes after taking the other drug. For reasons of simple handling, formulations are preferred in which the two drugs are administered to the patient close together and typically at the same time. After that, the timing of the administration of each drug may not be so important.
• the pharmaceutical composition according to the invention can preferably be used for treatment or prophylaxis and others.
• each of the clinical pictures mentioned below can be used as a single clinical picture as well as in combination with another of the named clinical pictures, but without being limited thereto.
• a further embodiment of the present invention comprises the use of the composition according to the invention for the manufacture of a medicament for the treatment or prevention of any of the indications for bladder dysfunction mentioned in the previous paragraph.
• Treatment of the above diseases or disorders is accomplished by delivering a therapeutically effective amount of the composition of the invention to a mammal. In most cases this is human, but the treatment of food animals (e.g. cattle) and pets (e.g. dogs, cats and horses) is expressly covered here.
• food animals e.g. cattle
• pets e.g. dogs, cats and horses
• the dosages to be used may be different from the dosages given herein.
• the new composition with a minimal level of deleterious side effects is expected to provide rapid relief to those suffering from the above diseases and disorders.
• Example N ° l composition from (-) - ethyl-2- [4- (2 - ⁇ [(IS, 2R) -2-hydroxy-2- (4-hydroxyphenyl) -1-methylethyl] amino ⁇ ethyl) -2 , 5-dimethylphenyloxy] acetate monohydrochloride and duloxetine: film-coated tablet 20 mg / 20 mg
• Example N ° 2 Composition of (-) - ethyl-2- [4- (2 - ⁇ [(IS, 2R) -2-hydroxy-2- (4-hydroxyphenyl) -l-methylethyl] amino ⁇ ethyl) -2 , 5-dimethylphenyloxy] acetate monohydrochloride and duloxetine: film-coated tablet 80 mg / 60 mg
• Eudragit L 30 D-55 is a 30% suspension. The water content is removed during spraying.
• Example N ° 3 Composition of (-) - ethyl-2- [4- (2 - ⁇ [(IS, 2R) -2-hydroxy-2- (4-hydroxyphenyl) -1-methylethyl] amino ⁇ ethyl) -2 , 5-dimethylphenyloxy] acetate monohydrochloride and duloxetine: hard gelatin capsule filled with pellets 20 mg / 20 mg

Landscapes

• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Urology & Nephrology (AREA)
• Emergency Medicine (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Priority Applications (13)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (2)

Family

ID=32241298

Family Applications (2)

Family Applications After (1)

Country Status (22)

Cited By (4)

Families Citing this family (32)

Family Cites Families (38)

• 2002
  • 2002-11-27 EP EP02026546A patent/EP1424079A1/en not_active Withdrawn
• 2003
  • 2003-03-11 UA UAA200506227A patent/UA81931C2/uk unknown
  • 2003-11-03 CN CNA2003801044257A patent/CN1717230A/zh active Pending
  • 2003-11-03 ES ES03778298T patent/ES2309371T3/es not_active Expired - Lifetime
  • 2003-11-03 CA CA002507266A patent/CA2507266A1/en not_active Abandoned
  • 2003-11-03 MX MXPA05005483A patent/MXPA05005483A/es not_active Application Discontinuation
  • 2003-11-03 PL PL03376259A patent/PL376259A1/xx unknown
  • 2003-11-03 JP JP2004554308A patent/JP2006509751A/ja active Pending
  • 2003-11-03 EP EP03778298A patent/EP1572181B1/de not_active Expired - Lifetime
  • 2003-11-03 DE DE50310046T patent/DE50310046D1/de not_active Expired - Fee Related
  • 2003-11-03 EA EA200500776A patent/EA009781B1/ru not_active IP Right Cessation
  • 2003-11-03 AU AU2003285312A patent/AU2003285312A1/en not_active Abandoned
  • 2003-11-03 HR HR20050467A patent/HRP20050467A2/xx not_active Application Discontinuation
  • 2003-11-03 AT AT03778298T patent/ATE399005T1/de not_active IP Right Cessation
  • 2003-11-03 RS RSP-2005/0392A patent/RS20050392A/sr unknown
  • 2003-11-03 WO PCT/EP2003/012225 patent/WO2004047830A2/de not_active Ceased
  • 2003-11-03 KR KR1020057009414A patent/KR20050088295A/ko not_active Withdrawn
  • 2003-11-03 BR BR0316535-3A patent/BR0316535A/pt not_active IP Right Cessation
  • 2003-11-03 EP EP05027827A patent/EP1640000A3/de not_active Withdrawn
  • 2003-11-05 EP EP03782183A patent/EP1567149A2/de not_active Withdrawn
  • 2003-11-05 CA CA002507343A patent/CA2507343A1/en not_active Abandoned
  • 2003-11-05 WO PCT/EP2003/012331 patent/WO2004047838A2/de not_active Ceased
  • 2003-11-05 AU AU2003289854A patent/AU2003289854A1/en not_active Abandoned
  • 2003-11-05 JP JP2004554318A patent/JP2006509752A/ja active Pending
• 2005
  • 2005-04-22 ZA ZA200503282A patent/ZA200503282B/en unknown
  • 2005-05-23 EC EC2005005814A patent/ECSP055814A/es unknown
  • 2005-05-24 US US11/136,165 patent/US20090012161A9/en not_active Abandoned
  • 2005-05-24 US US11/136,148 patent/US20050261328A1/en not_active Abandoned
  • 2005-06-23 NO NO20053088A patent/NO20053088L/no not_active Application Discontinuation
  • 2005-06-27 CO CO05062906A patent/CO5580754A2/es not_active Application Discontinuation

Also Published As

Similar Documents

Legal Events